Elanco Animal Health (ELAN)
undefined
undefined%
At close: undefined
12.10
-0.21%
After-hours Dec 13, 2024, 07:00 PM EST

Company Description

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.

It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.

Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health
Elanco Animal Health logo
Country United States
IPO Date Sep 20, 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 9,300
CEO Jeffrey N. Simmons

Contact Details

Address:
2500 Innovation Way
Greenfield, Indiana
United States
Website https://www.elanco.com

Stock Details

Ticker Symbol ELAN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739104
CUSIP Number 28414H103
ISIN Number US28414H1032
Employer ID 82-5497352
SIC Code 2834

Key Executives

Name Position
Jeffrey N. Simmons President, Chief Executive Officer & Director
Chris Keeley Senior Vice President & Chief Information Officer
Todd S. Young J.D. Executive Vice President & Chief Financial Officer
David S. Kinard Executive Vice President of Human Resources, Corporate Communications & Administration
Dr. Ellen de Brabander Ph.D. Executive Vice President of Research, Development & Regulatory Affairs
Dr. Ramiro Martin Cabral Executive Vice President of Elanco International
James M. Meer Senior Vice President & Chief Accounting Officer
Katy Grissom Head of Investor Relations
Shiv O'Neill Executive Vice President, General Counsel & Corporate Secretary
Timothy J. Bettington Executive Vice President of Corporate Strategy & Market Development

Latest SEC Filings

Date Type Title
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing
Dec 03, 2024 4 Filing